Onapristone
- Generic Name
- Onapristone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H39NO3
- CAS Number
- 96346-61-1
- Unique Ingredient Identifier
- H6H7G23O3N
- Background
Onapristone has been used in trials studying the treatment of Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, and Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Context Therapeutics Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05618613
- Locations
- 🇺🇸
Cancer Treatment Centers of America - Western Regional Medical Center, Phoenix, Arizona, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Cancer Treatment Centers of America - Midwestern Regional Center, Zion, Illinois, United States
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 11
- Registration Number
- NCT04738292
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 10
- Registration Number
- NCT04142892
- Locations
- 🇪🇸
Hospital ClÃnic de Barcelona, Barcelona, Spain
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital Universitario Sant Joan de Reus, Tarragona, Spain
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
- Conditions
- Interventions
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Arno Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT02052128
- Locations
- 🇫🇷
Institut Curie Oncologie Medicale, Paris, France
🇫🇷Centre Oscar Lambret, Lille, France
🇫🇷Institut Gustave Roussy, Villejuif, France
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Arno Therapeutics
- Target Recruit Count
- 75
- Registration Number
- NCT02049190
- Locations
- 🇬🇧
Inst of Cancer Research & Royal Marsden NHS Foundation Trust, Sutton Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.